Eli Lilly has posted a 15% decline in earnings for the first quarter, but sales were up 6%, with the antidepressant/fibromyalgia blockbuster Cymbalta and the lung cancer drug Alimta once again driving sales.
The most striking performance came from Cymbalta (duloxetine), up 13% to $908.8 million, Lilly’s best-selling drug continues to be the antipsychotic Zyprexa (olanzapine).
No comments:
Post a Comment